Modeling lung cancer survival probability after or side-effects from therapy

US8032308B2 · kind B2 · utility

Assignee

• Siemens Medical Solutions USA, Inc. · US

Inventors

• Shipeng Yu · Sunnyvale, US
• Glenn Fung · Madison, US
• Cary Dehing-Oberije · Brunssum, NL
• Dirk de Ruysscher · Tervuren, BE
• Sriram Krishnan · Bellevue, US
• R. Bharat Rao · Berwyn, US
• Philippe Lambin · Eijsden, NL

Key dates

• Filing date: Mar 6, 2009
• Grant date: Oct 4, 2011
• Expiry date: Mar 6, 2029

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61N2005/1041
• WIPO field: Medical technology
• WIPO sector: Instruments

Abstract

Modeling of prognosis of survivability, side-effect, or both is provided. For example, RILI is predicted using bullae information. The amount, volume or ratio of Bullae, even alone, may indicate the likelihood of complication, such as the likelihood of significant (e.g., stage 3) pneumonitis. As another example, RILI is predicted using uptake values of an imaging agent. Standardized uptake from a functional image (e.g., FDG uptake from a positron emission image), alone or in combination with other features, may indicate the likelihood of side-effect. In another example, survivability, such as two-year survivability, is predicted using blood biomarkers. The characteristics of a patient's blood may be measured and, alone or in combination with other features, may indicate the likelihood of survival. The modeling may be for survivability, side-effect, or both and may use one or more of the blood biomarker, uptake value, and bullae features.